Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.01 USD
+0.04 (4.47%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 41 - 60 ( 387 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q22 Results; Xpovio Beats Our Estimate; Impressive Myelofibrosis Data in ASH Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Nexpovio Granted Orphan Medicinal Product Designation For the Treatment of Myelofibrosis From the European Commission
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 19.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Results; Xpovio Sales Increase as Treatment Shifts to Earlier Lines; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
European Commission Grants Full Marketing For Nexpovio in MM Patients After at Least One Prior Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E